BiotechTube

ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Post-Menopausal Osteoporosis

Conditions

Post-Menopausal Osteoporosis

Trial Timeline

May 1, 2004 → May 1, 2008

NCT ID
NCT00081653

About ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]

ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] is a approved stage product being developed by Roche for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00081653. Target conditions include Post-Menopausal Osteoporosis.

What happened to similar drugs?

7 of 14 similar drugs in Post-Menopausal Osteoporosis were approved

Approved (7) Terminated (0) Active (7)
✅raloxifene + PlaceboEli LillyApproved
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅Raloxifene + Raloxifene + PlaceboEli LillyApproved
✅TeriparatideEli LillyApproved
✅ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
✅ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00545480ApprovedCompleted
NCT00545909ApprovedCompleted
NCT00551174ApprovedCompleted
NCT00081653ApprovedCompleted

Competing Products

19 competing products in Post-Menopausal Osteoporosis

See all competitors
ProductCompanyStageHype Score
raloxifene + PlaceboEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
Teriparatide + Zoledronic AcidEli LillyApproved
43
teriparatideEli LillyPhase 3
40
Raloxifene + Raloxifene + PlaceboEli LillyApproved
43
TeriparatideEli LillyApproved
43
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
MK0429MerckPhase 2
35
PTH134 + Placebo + ForsteoNovartisPhase 1
29
Placebo + Zoledronic acidNovartisPhase 3
40
zoledronic acid + Any oral bisphosphonates marketed in CanadaNovartisPre-clinical
26
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva] + AlendronateRocheApproved
43
ibandronate [Bonviva/Boniva] + ibandronate [Bonviva/Boniva]RocheApproved
43
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
40
IbandronateRochePhase 3
40
romosozumab HCP administration with PFSAmgenPhase 3
40
Romosozumab + Alendronate (Fosamax) + Placebo Romosozumab + Placebo AlendronateAmgenPhase 2
42
BAY3427080 + Placebo (for BAY3427080)BayerPhase 1/2
29